KYMR Kymera Therapeutics, Inc.
Price Chart
Executive Summary
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 on May 26, 2026, indicating intent to sell 13,130 shares of common stock valued at approximately $1.04 million. The shares were acquired through vesting of restricted stock units, and Chadwick has been executing sales under a 10b5-1 plan, with prior sales totaling over $14 million since March 2026. The filing is a routine advance notice under a pre-arranged trading plan and does not signal a change in business fundamentals.
Actionable Insight
This is a routine 10b5-1 plan filing by an officer; no material impact expected. Monitor for any deviation from the plan or acceleration of sales, but the filing itself does not warrant action.
Key Facts
- Officer Jeremy Chadwick filed Form 144 to sell 13,130 shares of common stock.
- Estimated aggregate market value of the proposed sale is $1,035,825.70 based on a filing date of May 26, 2026.
- Chadwick has been selling shares under a 10b5-1 plan, with prior sales totaling approximately $14.2 million from March to April 2026.
- Shares to be sold were acquired upon vesting of restricted stock units between March 2025 and May 2026.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 13,130 shares valued at ~$1.04 million, representing a small fraction of the $6.5B market cap.
Risk Factors
- Insider selling under a 10b5-1 plan is pre-arranged and not indicative of negative outlook.
- No material risk to company fundamentals from this filing.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005075 |
| Document: 0001950047-26-005075-index.html | 0001950047-26-005075 |
| Document: 0001950047-26-005075.txt | 0001950047-26-005075 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
2d ago
|
Press Release
| $73.80 awaiting T+5 | awaiting T+5 | — | $73.95 (+0.20%) |
|
May 26, 2026
14d ago
|
144
| $81.70 $73.21 | ▼ −10.39% | ▼ −10.86% | $73.95 (−9.49%) |
|
May 15, 2026
26d ago
|
Press Release
| $82.21 $78.89 | ▼ −4.04% | ▼ −5.00% | $73.95 (−10.05%) |
|
May 11, 2026
29d ago
|
144
| $83.55 $79.67 | ▼ −4.64% | ▼ −4.72% | $73.95 (−11.49%) |
|
Apr 23, 2026
6w ago
|
Press Release
| $87.17 $81.51 | ▼ −6.49% | ▼ −7.97% | $73.95 (−15.17%) |
|
Apr 15, 2026
7w ago
|
144
| $86.14 $87.17 | ▲ +1.20% | ▲ +0.21% | $73.95 (−14.15%) |
|
Apr 15, 2026
7w ago
|
144
| $86.14 $87.17 | ▲ +1.20% | ▲ +0.21% | $73.95 (−14.15%) |
|
Apr 15, 2026
8w ago
|
Insider Cluster
| $89.00 $88.77 | ▼ −0.26% | ▼ −1.90% | $73.95 (−16.91%) |
|
Apr 10, 2026
8w ago
|
Insider Cluster
| $85.05 $87.71 | ▲ +3.13% | ▼ −1.38% | $73.95 (−13.05%) |
|
Apr 1, 2026
9w ago
|
144
| $85.40 $85.05 | ▼ −0.41% | ▼ −4.03% | $73.95 (−13.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access